In a significant development for the medical research community, the National Institutes of Health (NIH) has announced a new funding opportunity under the title “NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional).” The grants notice, identified as PAR-24-049, seeks to encourage discretionary research that is pivotal for the planning of Phase II-IV clinical trials. These trials are crucial in the fight against a range of health issues, particularly those related to heart, lung, blood, and sleep disorders.
As detailed in the notice posted on November 3, 2023, the NIH is not imposing a cost-sharing or matching requirement for this grant, which falls under a series of CFDA numbers ranging from 93.233 to 93.840. These numbers represent the extensive spectrum of research areas the grant aims to cover, including the National Center on Sleep Disorders Research and various other domains such as cardiovascular, lung, blood diseases, and translation and implementation science research.
Opportunity ID: 350854
General Information
- Document Type: Grants Notice
- Funding Opportunity Number: PAR-24-049
- Funding Opportunity Title: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- Opportunity Category: Discretionary
- Funding Instrument Type: Grant
- Category of Funding Activity: Health
- Expected Number of Awards:
- CFDA Number(s):
- 93.233 — National Center on Sleep Disorders Research
- 93.837 — Cardiovascular Diseases Research
- 93.838 — Lung Diseases Research
- 93.839 — Blood Diseases and Resources Research
- 93.840 — Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- Cost Sharing or Matching Requirement: No
- Version: Synopsis 1
- Posted Date: Nov 03, 2023
- Last Updated Date: Nov 03, 2023
- Original Closing Date for Applications: Jan 07, 2027
- Current Closing Date for Applications: Jan 07, 2027
- Archive Date: Feb 12, 2027
- Estimated Total Program Funding:
- Award Ceiling: $
- Award Floor: $
Eligibility
- Eligible Applicants:
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- County governments
- State governments
- City or township governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Independent school districts
- Public housing authorities/Indian housing authorities
- Native American tribal governments (Federally recognized)
- Small businesses
- Special district governments
- For profit organizations other than small businesses
- Others (see text field entitled “Additional Information on Eligibility” for clarification)
- Additional Information on Eligibility: Other Eligible Applicants include the following:
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISISs)
- Eligible Agencies of the Federal Government
- Faith-based or Community-based Organizations
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Non-domestic (non-U.S.) Entities (Foreign Organizations)
- Regional Organizations
- Tribally Controlled Colleges and Universities (TCCUs)
- U.S. Territory or Possession
- Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
- Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
- Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Additional Information
- Agency Name: National Institutes of Health
- Description: This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI’s mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at the NHLBI website), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
- Link to Additional Information: https://grants.nih.gov/grants/guide/pa-files/PAR-24-049.html
- Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information - See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.